Physician profile
Daniel Sungwon Park
NPI 1851314488
$672.01
in general payments reported to CMS, 2019-2025
13 companies · $206 in 2025
The $206 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.35 · 2020: $12.27 · 2021: $96.69 · 2022: $42.53 · 2023: $153 · 2024: $104 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $268.47 | 2019-2025 | Puraply, Puraply Wound Matrix |
| Advanced Oxygen Therapy INC. | $69.28 | 2025 | Topical Oxygen Chamber For Extremities |
| Nabriva Therapeutics, Plc | $58.22 | 2021 | |
| Mimedx Group, INC. | $50.64 | 2024-2025 | |
| Convatec INC. | $37.07 | 2025 | |
| Djo, LLC | $33.66 | 2019-2024 | Dr Comfort |
| Abbvie INC. | $31.43 | 2023 | |
| Hydrofera LLC | $31.30 | 2023 | Hydrofera Blue |
| Kerecis Limited | $28.97 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Paratek Pharmaceuticals, INC. | $19.76 | 2025 | Nuzyra |
| Vertex Pharmaceuticals Incorporated | $17.30 | 2025 | |
| Merck Sharp & Dohme LLC | $13.64 | 2019 | |
| Fidia Pharma USA INC. | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.